Skip to Main Content

Noffar Bar, MD

Assistant Professor of Medicine (Hematology)
DownloadHi-Res Photo

About

Titles

Assistant Professor of Medicine (Hematology)

Biography

Noffar Bar, MD, is an Assistant Professor of Medicine (Hematology) at Yale School of Medicine and completed her internship and residency at the Mount Sinai Hospital and her fellowship at Yale. She received her medical degree from the American Medical Program at Tel Aviv University in New York.

Dr. Bar is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the International Myeloma Society. Dr. Bar’s research is focused on multiple myeloma and other plasma cell disorders. She specializes in all treatment modalities for myeloma including CAR T-cell therapy and stem cell transplant. She received grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar is dedicated to improving treatments for myeloma patients through innovative clinical trials. Additionally, Dr. Bar is a medical educator and a member of the Classical Hematology Disease team at Yale. She is interested in promoting high value care for hematology patients.

Appointments

Other Departments & Organizations

Education & Training

MD
American Medical Program at Tel Aviv University (2009)
BA
Tufts University (2005)

Research

Overview

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar's research interests focus on improving the care of patients with multiple myeloma and other plasma cell dyscrasias.

Research at a Glance

Yale Co-Authors

Frequent collaborators of Noffar Bar's published research.

Publications

2024

2023

Clinical Trials

Current Trials

Academic Achievements & Community Involvement

  • activity

    Cancer Medicine and Transfusion

  • activity

    American Society of Clinical Oncology

  • activity

    American Society of Hematology

  • activity

    How I manage relapsed/refractory myeloma; transplant vs. novel drugs in 2023

  • honor

    Hematology Oncology Fellowship Program Annual Research Award

Clinical Care

Overview

Noffar Bar, MD, is a hematologist who cares for patients with multiple myeloma, a cancer of the plasma cells—the white blood cells that make antibodies to protect the body against infection. She treats patients at all stages of multiple myeloma disease, from a precancerous stage called “smoldering” myeloma to newly diagnosed myeloma and relapsed refractory myeloma, a type that isn’t responding to treatment.

“I was drawn to myeloma during my residency,” says Dr. Bar. “I was interested in the fact that it was a multisystem disease that can affect different organs, such as the kidneys, the nerves, the clotting system, and the heart. But what I particularly loved was that we really were able to give patients a better quality of life.”

Treatments are designed to eliminate myeloma cells. “They are better than they were 10 years ago and continue to improve all the time,” she says. They include a range of options that are effective and tolerable and can help people live longer. Dr. Bar specializes in all treatment modalities for myeloma, including CAR T-cell therapy and stem cell transplant.

“I like to be honest and realistic with patients,” she says. “I let them know that multiple myeloma is an incurable disease, but there have been tremendous changes in how we care for it, and people are living longer to the point where we almost consider it a chronic disease. My goal is to get patients to live a good quality of life—where their symptoms are limited and we can keep them under control for many years.”

An assistant professor at Yale School of Medicine, Dr. Bar is involved with several clinical trials investigating treatment for myeloma. She is especially interested in the most effective ways to use T-cell redirection therapy, which involves directing the body’s T cells, which are part of the body’s immune system, to recognize and attack myeloma. “There are very different ways of doing this, and we want to understand how to use these agents most effectively,” she says.

Clinical Specialties

Hematologic Oncology; Hematology

Fact Sheets

Yale Medicine News

Get In Touch

Contacts

Appointment Number
Clinic Fax Number

Locations

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.